Agenus Inc is an American biotechnology company. Its main target are immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharp & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs.
| Website: | www.agenusbio.com |
| Email: | investor@agenusbio.com |
| Main Phone: | +1 781 674-4400 |
| Address: | 3 Forbes Road |
| State: | MA |
| City / Town: | Lexington |
| Country: | USA |
| Postal Code: | 02421 |
| Exchange: | NSC |
| CEO: | Garo H Armen |
| Employees: | 255 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
Gathering Data... Please wait Agenus Inc is an American biotechnology company. Its main target are immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharp & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs.
| Website: | www.agenusbio.com |
| Email: | investor@agenusbio.com |
| Main Phone: | +1 781 674-4400 |
| Address: | 3 Forbes Road |
| State: | MA |
| City / Town: | Lexington |
| Country: | USA |
| Postal Code: | 02421 |
| Exchange: | NSC |
| CEO: | Garo H Armen |
| Employees: | 255 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
| Last Price 3.61 | Change $ 0.07 | Change % 1.98 | Tick N/A |
| Bid 3.53 | Bid Size 2,000.00 | Ask 3.68 | Ask Size 600.00 |
| Open 3.56 | High 3.69 | Low 3.50 | Prev Close 3.54 |
| Last Trade | Volume 1.3 mi | 52 Wk Hi 6.19 | 52 Wk Low 1.54 |
| Market Cap 473.3 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 131,106,797.00 | EPS (TTM) -1.41 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 3 | 18 |
| Number of Buys | 3 | 12 |
| Number of Sells | 0 | 6 |
| Net Activity | 53050 | -26157 |
| Last 10 Buys | Shares |
|---|---|
| Garo H Armen | 1,000 |
| Garo H Armen | 1,000 |
| Garo H Armen | 1,000 |
| Garo H Armen | 1,000 |
| Garo H Armen | 1,000 |
| Garo H Armen | 1,000 |
| Ozer Baysal | 1,000 |
| Garo H Armen | 1,000 |
| Garo H Armen | 1,000 |
| Garo H Armen | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Jennifer Buell | 1,000 |
| Alex Duncan | 1,000 |
| Christine Klaskin | 1,000 |
| Ozer Baysal | 1,000 |
| Karen Valentine | 1,000 |
| Garo H Armen | 1,000 |
| Garo H Armen | 1,000 |
| Garo H Armen | 1,000 |
| Kerry Wentworth | 1,000 |
| Karen Valentine | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 7 | 7 | 7 | 7 |
| Low Target Price Estimate | 7 | 7 | 7 | 7 |
| Mean Target Price Estimate | 7 | 7 | 7 | 7 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 03/16/18 | 03/16/18 | 03/16/18 | 03/16/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 47 | 2018-05-11 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 58 | 2018-05-11 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 122 | 2018-05-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-05-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-05-07 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 89 | 2018-04-26 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-04-03 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-04-03 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-04-03 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-04-03 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
